Target genes: Bone proteins

Vitamin D

Volumn , Issue , 2011, Pages 411-424

  Atkins, Gerald J ^a   Findlay, David M ^a   Anderson, Paul H ^b,c   Morris, Howard A ^b,c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b SA Pathology   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863864473     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10023-X     Document Type: Chapter

References (150)

1. Wang T.T., Tavera-Mendoza L.E., Laperriere D., Libby E., MacLeod N.B., Nagai Y., et al. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol. Endocrinol. 2005, 19:2685-2695.
2. Suda T., Ueno Y., Fujii K., Shinki T. Vitamin D and bone. J. Cell Biochem. 2003, 88:259-266.
3. Underwood J.L., DeLuca H.F. Vitamin D is not directly necessary for bone growth and mineralization. Am. J. Physiol. 1984, 246:E493-498.
4. Weinstein R.S., Underwood J.L., Hutson M.S., DeLuca H.F. Bone histomorphometry in vitamin D-deficient rats infused with calcium and phosphorus. Am. J. Physiol. 1984, 246:E499-505.
5. Amling M., Priemel M., Holzmann T., Chapin K., Rueger J.M., Baron R., et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 1999, 140:4982-4987.
6. S.J. Van Cromphaut, M. Dewerchin, J.G. Hoenderop, I. Stockmans, E. Van Herck, S. Kato, et al., Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects, Proc. Nat. Acad. Sci. USA 98 (2001) 13324-13329.
7. Sooy K., Sabbagh Y., Demay M.B. Osteoblasts lacking the vitamin D receptor display enhanced osteogenic potential in vitro. J. Cell Biochem. 2005, 94:81-87.
8. Marks H.D., Fleet J.C., Peleg S. Transgenic expression of the human Vitamin D receptor (hVDR) in the duodenum of VDR-null mice attenuates the age-dependent decline in calcium absorption. J. Steroid Biochem. Mol. Biol. 2007, 103:513-516.
9. van Driel M., Koedam M., Buurman C.J., Hewison M., Chiba H., Uitterlinden A.G., et al. Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. Faseb J. 2006, 20:2417-2419.
10. van Driel M., Pols H.A., van Leeuwen J.P. Osteoblast differentiation and control by vitamin D and vitamin D metabolites. Curr. Pharm. Des. 2004, 10:2535-2555.
11. Atkins G.J., Anderson P.H., Findlay D.M., Welldon K.J., Vincent C., Zannettino A.C., et al. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone 2007, 40:1517-1528.
12. Anderson P.H., Atkins G.J., Findlay D.M., Oloughlin P.D., Welldon K., Vincent C., et al. RNAi-mediated silencing of CYP27B1 abolishes 1,25(OH)2D3 synthesis and reduces osteocalcin and CYP24 mRNA expression in human osteosarcoma (HOS) cells. J. Steroid Biochem. Mol. Biol. 2007, 103:601-605.
13. Anderson P.H., Atkins G.J. The skeleton as an intracrine organ for vitamin D metabolism. Mol. Aspects Med. 2008, 29:397-406.
14. Zehnder D., Bland R., Williams M.C., McNinch R.W., Howie A.J., Stewart P.M., et al. Extrarenal expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase. J. Clin. Endocrinol. Metab. 2001, 86:888-894.
15. Zehnder D., Hewison M. The renal function of 25-hydroxyvitamin D3-1alpha-hydroxylase. Mol. Cell Endocrinol. 1999, 151:213-220.
16. Hendrix I., Anderson P.H., Omdahl J.L., May B.K., Morris H.A. Response of the 5'-flanking region of the human 25-hydroxyvitamin D 1alpha-hydroxylase gene to physiological stimuli using a transgenic mouse model. J. Mol. Endocrinol. 2005, 34:237-245.
17. Barbour G.L., Coburn J.W., Slatopolsky E., Norman A.W., Horst R.L. Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. N. Engl. J. Med. 1981, 305:440-443.
18. Weisman Y., Vargas A., Duckett G., Reiter E., Root A.W. Synthesis of 1,25-dihydroxyvitamin D in the nephrectomized pregnant rat. Endocrinology 1978, 103:1992-1996.
19. Anderson P.H., O'Loughlin P.D., May B.K., Morris H.A. Determinants of circulating 1,25-dihydroxyvitamin D3 levels: the role of renal synthesis and catabolism of vitamin D. J. Steroid Biochem. Mol. Biol. 2004, 89-90:111-113.
20. Anderson P.H., O'Loughlin P.D., May B.K., Morris H.A. Modulation of CYP27B1 and CYP24 mRNA expression in bone is independent of circulating 1,25(OH)2D3 levels. Bone 2005, 36:654-662.
21. Huang D.C., Papavasiliou V., Rhim J.S., Horst R.L., Kremer R. Targeted disruption of the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in ras-transformed keratinocytes demonstrates that locally produced 1alpha,25-dihydroxyvitamin D3 suppresses growth and induces differentiation in an autocrine fashion. Mol. Cancer Res. 2002, 1:56-67.
22. Lehmann B., Meurer M. Extrarenal sites of calcitriol synthesis: the particular role of the skin. Recent Results. Cancer Res. 2003, 164:135-145.
23. Howard G.A., Turner R.T., Sherrard D.J., Baylink D.J. Human bone cells in culture metabolize 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3. J. Biol. Chem. 1981, 256:7738-7740.
24. Ichikawa F., Sato K., Nanjo M., Nishii Y., Shinki T., Takahashi N., et al. Mouse primary osteoblasts express vitamin D3 25-hydroxylase mRNA and convert 1 alpha-hydroxyvitamin D3 into 1 alpha,25-dihydroxyvitamin D3. Bone 1995, 16:129-135.
25. Turner R.T., Avioli R.C., Bell N.H. Extrarenal metabolism of 25-hydroxycholecalciferol in the rat: regulation by 1,25-dihydroxycholecalciferol. Calc. Tissue Int. 1984, 36:274-278.
26. Kogawa M., Anderson P.H., Findlay D.M., Morris H.A., Atkins G.J. The metabolism of 25-(OH)vitamin D(3) by osteoclasts and their precursors regulates the differentiation of osteoclasts. J. Steroid Biochem. Mol. Biol. 2010, 121:277-280.
27. Kogawa M., Findlay D.M., Anderson P.H., Ormsby R., Vincent C., Morris H.A., et al. Osteoclastic metabolism of 25(OH)-vitamin D3: a potential mechanism for optimization of bone resorption. Endocrinology 2010, 151:4613-4625.
28. Panda D.K., Al Kawas S., Seldin M.F., Hendy G.N., Goltzman D. 25-Hydroxyvitamin D 1alpha-hydroxylase: structure of the mouse gene, chromosomal assignment, and developmental expression. J. Bone Miner. Res. 2001, 16:46-56.
29. Panda D.K., Miao D., Tremblay M.L., Sirois J., Farookhi R., Hendy G.N., et al. Targeted ablation of the 25-hydroxyvitamin D 1alpha-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc. Natl. Acad. Sci. USA 2001, 98:7498-7503.
30. Anderson P.H., Iida S., Tyson J.H., Turner A.G., Morris H.A. Bone CYP27B1 gene expression is increased with high dietary calcium and in mineralising osteoblasts. J. Steroid Biochem. Mol. Biol. 2010, 121:71-75.
31. Need A.G., Horowitz M., Morris H.A., Moore R., Nordin C. Seasonal change in osteoid thickness and mineralization lag time in ambulant patients. J. Bone Miner. Res. 2007, 22:757-761.
32. Priemel M., von Domarus C., Klatte T.O., Kessler S., Schlie J., Meier S., et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J. Bone Miner. Res. 2009.
33. Anderson P.H., O'Loughlin P.D., May B.K., Morris H.A. Quantification of mRNA for the vitamin D metabolizing enzymes CYP27B1 and CYP24 and vitamin D receptor in kidney using real-time reverse transcriptase-polymerase chain reaction. J. Mol. Endocrinol. 2003, 31:123-132.
34. Anderson P.H., Sawyer R.K., May B.K., O'Loughlin P.D., Morris H.A. 25-Hydroxyvitamin D requirement for maintaining skeletal health utilising a Sprague-Dawley rat model. J. Steroid Biochem. Mol. Biol. 2007, 103:592-595.
35. Atkins G.J., Anderson P.H., Findlay D.M., Welldon K.J., Vincent C., Zannettino A.C., et al. Metabolism of vitamin D(3) in human osteoblasts: evidence for autocrine and paracrine activities of 1alpha,25-dihydroxyvitamin D(3). Bone 2007, 40:1517-1528.
36. Bikle D.D., Gee E., Halloran B., Kowalski M.A., Ryzen E., Haddad J.G. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J. Clin. Endocrinol. Metab. 1986, 63:954-959.
37. Nykjaer A., Dragun D., Walther D., Vorum H., Jacobsen C., Herz J., et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999, 96:507-515.
38. Christensen E.I., Birn H. Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am. J. Physiol. Renal. Physiol. 2001, 280:F562-573.
39. Takeda S., Yoshizawa T., Nagai Y., Yamato H., Fukumoto S., Sekine K., et al. Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice. Endocrinology 1999, 140:1005-1008.
40. Adams J.S., Beeker T.G., Hongo T., Clemens T.L. Constitutive expression of a vitamin D 1-hydroxylase in a myelomonocytic cell line: a model for studying 1,25-dihydroxyvitamin D production in vitro. J. Bone Miner. Res. 1990, 5:1265-1269.
41. Dusso A.S., Finch J., Brown A., Ritter C., Delmez J., Schreiner G., et al. Extrarenal production of calcitriol in normal and uremic humans. J. Clin. Endocrinol. Metab. 1991, 72:157-164.
42. Reichel H., Koeffler H.P., Norman A.W. Synthesis in vitro of 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 by interferon-gamma-stimulated normal human bone marrow and alveolar macrophages. J. Biol. Chem. 1987, 262:10931-10937.
43. Pedrozo H.A., Boyan B.D., Mazock J., Dean D.D., Gomez R., Schwartz Z. TGFbeta1 regulates 25-hydroxyvitamin D3 1alpha- and 24-hydroxylase activity in cultured growth plate chondrocytes in a maturation-dependent manner. Calcif. Tissue Int. 1999, 64:50-56.
44. Weber L., Hugel U., Reichrath J., Sieverts H., Mehls O., Klaus G. Cultured rat growth plate chondrocytes express low levels of 1alpha-hydroxylase. Recent Results Cancer Res. 2003, 164:147-149.
45. Masuyama R., Stockmans I., Torrekens S., Van Looveren R., Maes C., Carmeliet P., et al. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J. Clin. Invest. 2006, 116:3150-3159.
46. Naja R.P., Dardenne O., Arabian A., St Arnaud R. Chondrocyte-specific modulation of Cyp27b1 expression supports a role for local synthesis of 1,25-dihydroxyvitamin D3 in growth plate development. Endocrinology 2009, 150:4024-4032.
47. Anderson P.H., Sawyer R.K., Moore A.J., May B.K., O'Loughlin P.D., Morris H.A. Vitamin D depletion induces RANKL-mediated osteoclastogenesis and bone loss in a rodent model. J. Bone Miner. Res. 2008, 23:1789-1797.
48. Robey G.P., Boskey A.L. The composition of bone. Primer on the metabolic bone diseases and disorders of mineral metabolism 2008, American Society for Bone and Mineral Research, Washington D.C. seventh ed.
49. Matsumoto T., Igarashi C., Takeuchi Y., Harada S., Kikuchi T., Yamato H., et al. Stimulation by 1,25-dihydroxyvitamin D3 of in vitro mineralization induced by osteoblast-like MC3T3-E1 cells. Bone 1991, 12:27-32.
50. Rickard D.J., Kazhdan I., Leboy P.S. Importance of 1,25-dihydroxyvitamin D3 and the nonadherent cells of marrow for osteoblast differentiation from rat marrow stromal cells. Bone 1995, 16:671-678.
51. Atkins G.J., Kostakis P., Pan B., Farrugia A., Gronthos S., Evdokiou A., et al. RANKL expression is related to the differentiation state of human osteoblasts. J. Bone Miner. Res. 2003, 18:1088-1098.
52. Chen J., Thomas H.F., Sodek J. Regulation of bone sialoprotein and osteopontin mRNA expression by dexamethasone and 1,25-dihydroxyvitamin D3 in rat bone organ cultures. Connect. Tissue Res. 1996, 34:41-51.
53. Abe E., Miyaura C., Sakagami H., Takeda M., Konno K., Yamazaki T., et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA 1981, 78:4990-4994.
54. Tanaka H., Abe E., Miyaura C., Kuribayashi T., Konno K., Nishii Y., et al. 1 Alpha,25-dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60). Biochem. J. 1982, 204:713-719.
55. Walsh M.C., Choi Y. Biology of the TRANCE axis. Cytokine Growth Factor Rev. 2003, 14:251-263.
56. Xing L., Schwarz E.M., Boyce B.F. Osteoclast precursors, RANKL/RANK, and immunology. Immunol. Rev. 2005, 208:19-29.
57. Simmons P.J., Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991, 78:55-62.
58. Thomas G.P., Baker S.U., Eisman J.A., Gardiner E.M. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J. Endocrinol. 2001, 170:451-460.
59. Kraichely D.M., MacDonald P.N. Transcriptional activation through the vitamin D receptor in osteoblasts. Front. Biosci. 1998, 3:d821-833.
60. Kitazawa R., Kitazawa S., Maeda S. Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. Biochim. Biophys. Acta 1999, 1445:134-141.
61. Stern P.H. Vitamin D and bone. Kidney. Int. (Suppl. 29) 1990, S17-21.
62. Gurlek A., Kumar R. Regulation of osteoblast growth by interactions between transforming growth factor-beta and 1alpha,25-dihydroxyvitamin D3. Crit. Rev. Eukaryot. Gene Expr. 2001, 11:299-317.
63. Skjodt H., Gallagher J.A., Beresford J.N., Couch M., Poser J.W., Russell R.G. Vitamin D metabolites regulate osteocalcin synthesis and proliferation of human bone cells in vitro. J. Endocrinol. 1985, 105:391-396.
64. van den Bemd G.J., Pols H.A., Birkenhager J.C., Kleinekoort W.M., van Leeuwen J.P. Differential effects of 1,25-dihydroxyvitamin D3-analogs on osteoblast-like cells and on in vitro bone resorption. J. Steroid Biochem. Mol. Biol. 1995, 55:337-346.
65. Owen T.A., Aronow M.S., Barone L.M., Bettencourt B., Stein G.S., Lian J.B. Pleiotropic effects of vitamin D on osteoblast gene expression are related to the proliferative and differentiated state of the bone cell phenotype: dependency upon basal levels of gene expression, duration of exposure, and bone matrix competency in normal rat osteoblast cultures. Endocrinology 1991, 128:1496-1504.
66. Murray S., Glackin C., Murray E. Variation in 1,25-dihydroxyvitamin D3 regulation of proliferation and alkaline phosphatase activity in late-passage rat osteoblastic cell lines. J. Steroid Biochem. Mol. Biol. 1993, 46:227-233.
67. Chen T.L., Cone C.M., Feldman D. Effects of 1 alpha,25-dihydroxyvitamin D3 and glucocorticoids on the growth of rat and mouse osteoblast-like bone cells. Calcif. Tissue Int. 1983, 35:806-811.
68. Kanatani M., Sugimoto T., Fukase M., Chihara K. Effect of 1,25-dihydroxyvitamin D3 on the proliferation of osteoblastic MC3T3-E1 cells by modulating the release of local regulators from monocytes. Biochem. Biophys. Res. Commun. 1993, 190:529-535.
69. Rubin J., Fan X., Thornton D., Bryant R., Biskobing D. Regulation of murine osteoblast macrophage colony-stimulating factor production by 1,25(OH)2D3. Calcif. Tissue Int. 1996, 59:291-296.
70. Lyons A.B., Parish C.R. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 1994, 171:131-137.
71. Stein G.S., Lian J.B., Owen T.A. Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. Faseb J. 1990, 4:3111-3123.
72. Franceschi R.T., Romano P.R., Park K.Y. Regulation of type I collagen synthesis by 1,25-dihydroxyvitamin D3 in human osteosarcoma cells. J. Biol. Chem. 1988, 263:18938-18945.
73. Rowe D.W., Kream B.E. Regulation of collagen synthesis in fetal rat calvaria by 1,25-dihydroxyvitamin D3. J. Biol. Chem. 1982, 257:8009-8015.
74. Thomson B.M., Atkinson S.J., Reynolds J.J., Meikle M.C. Degradation of type I collagen films by mouse osteoblasts is stimulated by 1,25 dihydroxyvitamin D3 and inhibited by human recombinant TIMP (tissue inhibitor of metalloproteinases). Biochem. Biophys. Res. Commun. 1987, 148:596-602.
75. Broess M., Riva A., Gerstenfeld L.C. Inhibitory effects of 1,25(OH)2 vitamin D3 on collagen type I, osteopontin, and osteocalcin gene expression in chicken osteoblasts. J. Cell Biochem. 1995, 57:440-451.
76. Narisawa S., Frohlander N., Millan J.L. Inactivation of two mouse alkaline phosphatase genes and establishment of a model of infantile hypophosphatasia. Dev. Dyn. 1997, 208:432-446.
77. Watts N.B. Clinical utility of biochemical markers of bone remodeling. Clin. Chem. 1999, 45:1359-1368.
78. Noda M., Yoon K., Rodan G.A., Koppel D.E. High lateral mobility of endogenous and transfected alkaline phosphatase: a phosphatidylinositol-anchored membrane protein. J. Cell Biol. 1987, 105:1671-1677.
79. Manolagas S.C., Burton D.W., Deftos L.J. 1,25-Dihydroxyvitamin D3 stimulates the alkaline phosphatase activity of osteoblast-like cells. J. Biol. Chem. 1981, 256:7115-7117.
80. Imai K., Neuman M.W., Kawase T., Saito S. Calcium in osteoblast-enriched bone cells. Bone 1992, 13:217-223.
81. Halstead L.R., Scott M.J., Rifas L., Avioli L.V. Characterization of osteoblast-like cells from normal adult rat femoral trabecular bone. Calcif. Tissue Int. 1992, 50:93-95.
82. Bodine P.V., Trailsmith M., Komm B.S. Development and characterization of a conditionally transformed adult human osteoblastic cell line. J. Bone Miner. Res. 1996, 11:806-819.
83. Hicok K.C., Thomas T., Gori F., Rickard D.J., Spelsberg T.C., Riggs B.L. Development and characterization of conditionally immortalized osteoblast precursor cell lines from human bone marrow stroma. J. Bone Miner. Res. 1998, 13:205-217.
84. El-Maadawy S., Kaartinen M.T., Schinke T., Murshed M., Karsenty G., McKee M.D. Cartilage formation and calcification in arteries of mice lacking matrix Gla protein. Connect. Tissue Res. 2003, 44:272-278.
85. Fraser J.D., Otawara Y., Price P.A. 1,25-Dihydroxyvitamin D3 stimulates the synthesis of matrix gamma-carboxyglutamic acid protein by osteosarcoma cells. Mutually exclusive expression of vitamin K-dependent bone proteins by clonal osteoblastic cell lines. J. Biol. Chem. 1988, 263:911-916.
86. Fraser J.D., Price P.A. Induction of matrix Gla protein synthesis during prolonged 1,25-dihydroxyvitamin D3 treatment of osteosarcoma cells. Calcif. Tissue Int. 1990, 46:270-279.
87. Barone L.M., Owen T.A., Tassinari M.S., Bortell R., Stein G.S., Lian J.B. Developmental expression and hormonal regulation of the rat matrix Gla protein (MGP) gene in chondrogenesis and osteogenesis. J. Cell Biochem. 1991, 46:351-365.
88. Yoon K., Buenaga R., Rodan G.A. Tissue specificity and developmental expression of rat osteopontin. Biochem. Biophys. Res. Commun. 1987, 148:1129-1136.
89. Beresford J.N., Joyner C.J., Devlin C., Triffitt J.T. The effects of dexamethasone and 1,25-dihydroxyvitamin D3 on osteogenic differentiation of human marrow stromal cells in vitro. Arch. Oral. Biol. 1994, 39:941-947.
90. Matsue M., Kageyama R., Denhardt D.T., Noda M. Helix-loop-helix-type transcription factor (HES-1) is expressed in osteoblastic cells, suppressed by 1,25(OH)2 vitamin D3, and modulates 1,25(OH)2 vitamin D3 enhancement of osteopontin gene expression. Bone 1997, 20:329-334.
91. Bellows C.G., Reimers S.M., Heersche J.N. Expression of mRNAs for type-I collagen, bone sialoprotein, osteocalcin, and osteopontin at different stages of osteoblastic differentiation and their regulation by 1,25 dihydroxyvitamin D3. Cell Tissue Res. 1999, 297:249-259.
92. Addison W., Masica D., Gray J., McKee M.D. Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J. Bone Miner. Res. 2010, 25:695-705.
93. Noda M., Rodan G.A. Transcriptional regulation of osteopontin production in rat osteoblast-like cells by parathyroid hormone. J. Cell. Biol. 1989, 108:713-718.
94. Staal A., Van Wijnen A.J., Desai R.K., Pols H.A., Birkenhager J.C., Deluca H.F., et al. Antagonistic effects of transforming growth factor-beta on vitamin D3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamin E response elements. Endocrinology 1996, 137:2001-2011.
95. Ganss B., Kim R.H., Sodek J. Bone sialoprotein. Crit. Rev. Oral. Biol. Med. 1999, 10:79-98.
96. Oldberg A., Jirskog-Hed B., Axelsson S., Heinegard D. Regulation of bone sialoprotein mRNA by steroid hormones. J. Cell Biol. 1989, 109:3183-3186.
97. Li J.J., Sodek J., Oldberg A., Jirskog-Hed B., Axelsson S., Heinegard D. Cloning and characterization of the rat bone sialoprotein gene promoter. Regulation of bone sialoprotein mRNA by steroid hormones. Biochem. J. 1993, 289:625-629.
98. Kim R.H., Li J.J., Ogata Y., Yamauchi M., Freedman L.P., Sodek J. Identification of a vitamin D3-response element that overlaps a unique inverted TATA box in the rat bone sialoprotein gene. Biochem. J. 1996, 318:219-226.
99. Sodek J., Li J.J., Kim R.H., Ogata Y., Yamauchi M. Characterization of the bone sialoprotein (BSP) gene promoter. Connect. Tissue Res. 1996, 35:23-31.
100. Sodek J., Kim R.H., Ogata Y., Li J., Yamauchi M., Zhang Q., et al. Regulation of bone sialoprotein gene transcription by steroid hormones. Connect. Tissue. Res. 1995, 32:209-217.
101. Chang P.L., Prince C.W. 1 Alpha,25-dihydroxyvitamin D3 stimulates synthesis and secretion of nonphosphorylated osteopontin (secreted phosphoprotein 1) in mouse JB6 epidermal cells. Cancer. Res. 1991, 51:2144-2150.
102. Pockwinse S.M., Stein J.L., Lian J.B., Stein G.S. Developmental stage-specific cellular responses to vitamin D and glucocorticoids during differentiation of the osteoblast phenotype: interrelationship of morphology and gene expression by in situ hybridization. Exp. Cell Res. 1995, 216:244-260.
103. Price P.A., Williamson M.K., Lothringer J.W. Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J. Biol. Chem. 1981, 256:12760-12766.
104. Ducy P., Desbois C., Boyce B., Pinero G., Story B., Dunstan C., et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996, 382:448-452.
105. Chenu C., Colucci S., Grano M., Zigrino P., Barattolo R., Zambonin G., et al. Osteocalcin induces chemotaxis, secretion of matrix proteins, and calcium-mediated intracellular signaling in human osteoclast-like cells. J. Cell Biol. 1994, 127:1149-1158.
106. Ivaska K.K., Hentunen T.A., Vaaraniemi J., Ylipahkala H., Pettersson K., Vaananen H.K. Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J. Biol. Chem. 2004, 279:18361-18369.
107. Beresford J.N., Gallagher J.A., Poser J.W., Russell R.G. Production of osteocalcin by human bone cells in vitro. Effects of 1,25(OH)2D3, 24,25(OH)2D3, parathyroid hormone, and glucocorticoids. Metab. Bone Dis. Relat. Res. 1984, 5:229-234.
108. Lian J., Stewart C., Puchacz E., Mackowiak S., Shalhoub V., Collart D., et al. Structure of the rat osteocalcin gene and regulation of vitamin D-dependent expression. Proc. Natl. Acad. Sci. USA 1989, 86:1143-1147.
109. Lajeunesse D., Kiebzak G.M., Frondoza C., Sacktor B. Regulation of osteocalcin secretion by human primary bone cells and by the human osteosarcoma cell line MG-63. Bone Miner. 1991, 14:237-250.
110. Ingram R.T., Bonde S.K., Riggs B.L., Fitzpatrick L.A. Effects of transforming growth factor beta (TGF beta) and 1,25 dihydroxyvitamin D3 on the function, cytochemistry and morphology of normal human osteoblast-like cells. Differentiation 1994, 55:153-163.
111. Mosavin R., Mellon W.S. Posttranscriptional regulation of osteocalcin mRNA in clonal osteoblast cells by 1,25-dihydroxyvitamin D3. Arch. Biochem. Biophys. 1996, 332:142-152.
112. Lajeunesse D., Frondoza C., Schoffield B., Sacktor B. Osteocalcin secretion by the human osteosarcoma cell line MG-63. J. Bone. Miner. Res. 1990, 5:915-922.
113. Hosoda K., Kanzaki S., Eguchi H., Kiyoki M., Yamaji T., Koshihara Y., et al. Secretion of osteocalcin and its propeptide from human osteoblastic cells: dissociation of the secretory patterns of osteocalcin and its propeptide. J. Bone Miner. Res. 1993, 8:553-565.
114. Zhang R., Ducy P., Karsenty G. 1,25-Dihydroxyvitamin D3 inhibits Osteocalcin expression in mouse through an indirect mechanism. J. Biol. Chem. 1997, 272:110-116.
115. Lian J.B., Shalhoub V., Aslam F., Frenkel B., Green J., Hamrah M., et al. Species-specific glucocorticoid and 1,25-dihydroxyvitamin D responsiveness in mouse MC3T3-E1 osteoblasts: dexamethasone inhibits osteoblast differentiation and vitamin D down-regulates osteocalcin gene expression. Endocrinology 1997, 138:2117-2127.
116. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764.
117. Otto F., Thornell A.P., Crompton T., Denzel A., Gilmour K.C., Rosewell I.R., et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997, 89:765-771.
118. Javed A., Gutierrez S., Montecino M., van Wijnen A.J., Stein J.L., Stein G.S., et al. Multiple Cbfa/AML sites in the rat osteocalcin promoter are required for basal and vitamin D-responsive transcription and contribute to chromatin organization. Mol. Cell. Biol. 1999, 19:7491-7500.
119. Aslam F., McCabe L., Frenkel B., van Wijnen A.J., Stein G.S., Lian J.B., et al. AP-1 and vitamin D receptor (VDR) signaling pathways converge at the rat osteocalcin VDR element: requirement for the internal activating protein-1 site for vitamin D-mediated trans-activation. Endocrinology 1999, 140:63-70.
120. Grigoriadis A.E., Schellander K., Wang Z.Q., Wagner E.F. Osteoblasts are target cells for transformation in c-fos transgenic mice. J. Cell Biol. 1993, 122:685-701.
121. Owen T.A., Bortell R., Yocum S.A., Smock S.L., Zhang M., Abate C., et al. Coordinate occupancy of AP-1 sites in the vitamin D-responsive and CCAAT box elements by Fos-Jun in the osteocalcin gene: model for phenotype suppression of transcription. Proc. Natl. Acad. Sci. USA 1990, 87:9990-9994.
122. McCabe L.R., Banerjee C., Kundu R., Harrison R.J., Dobner P.R., Stein J.L., et al. Developmental expression and activities of specific fos and jun proteins are functionally related to osteoblast maturation: role of Fra-2 and Jun D during differentiation. Endocrinology 1996, 137:4398-4408.
123. Bonewald L.F. Osteocyte messages from a bony tomb. Cell Metab. 2007, 5:410-411.
124. Bonewald L.F. Osteocytes as dynamic, multifunctional cells. Ann. N.Y. Acad. Sci. 2007, 1116:281-290.
125. Feng J.Q., Ward L.M., Liu S., Lu Y., Xie Y., Yuan B., et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet. 2006, 38:1310-1315.
126. Kolek O.I., Hines E.R., Jones M.D., LeSueur L.K., Lipko M.A., Kiela P.R., et al. 1Alpha,25-dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289:G1036-1042.
127. Tang W.J., Wang L.F., Xu X.Y., Zhou Y., Jin W.F., Wang H.F., Gao J. Autocrine/paracrine action of vitamin D on FGF23 expression in cultured rat osteoblasts. Calcif. Tissue Int. 2010, 86:404-410.
128. Inoue Y., Segawa H., Kaneko I., Yamanaka S., Kusano K., Kawakami E., et al. Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem. J. 2005, 390:325-331.
129. Krajisnik T., Bjorklund P., Marsell R., Ljunggren O., Akerstrom G., Jonsson K.B., et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J. Endocrinol. 2007, 195:125-131.
130. ADHR Consortium Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26 (2000) 345-348.
131. Rowe P.S. The wrickkened pathways of FGF23, MEPE and PHEX. Crit. Rev. Oral. Biol. Med. 2004, 15:264-281.
132. Liu S., Zhou J., Tang W., Jiang X., Rowe D.W., Quarles L.D. Pathogenic role of Fgf23 in Hyp mice. Am. J. Physiol. Endocrinol. Metab. 2006, 291:E38-49.
133. Liu S., Zhou J., Tang W., Menard R., Feng J.Q., Quarles L.D. Pathogenic role of Fgf23 in Dmp1-null mice. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E254-261.
134. Imel E.A., DiMeglio L.A., Hui S.L., Carpenter T.O., Econs M.J. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J. Clin. Endocrinol. Metab. 2010, 95:1846-1850.
135. Fisher L.W., Fedarko N.S. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect. Tissue Res. 2003, 44(Suppl. 1):33-40.
136. George A., Sabsay B., Simonian P.A., Veis A. Characterization of a novel dentin matrix acidic phosphoprotein. Implications for induction of biomineralization. J. Biol. Chem. 1993, 268:12624-12630.
137. Qin C., D'Souza R., Feng J.Q. Dentin matrix protein 1 (DMP1): new and important roles for biomineralization and phosphate homeostasis. J. Dent. Res. 2007, 86:1134-1141.
138. Farrow E.G., Davis S.I., Ward L.M., Summers L.J., Bubbear J.S., Keen R., et al. Molecular analysis of DMP1 mutants causing autosomal recessive hypophosphatemic rickets. Bone 2009, 44:287-294.
139. Mimura H., Cao X., Ross F.P., Chiba M., Teitelbaum S.L. 1,25-Dihydroxyvitamin D3 transcriptionally activates the beta 3-integrin subunit gene in avian osteoclast precursors. Endocrinology 1994, 134:1061-1066.
140. Medhora M.M., Teitelbaum S., Chappel J., Alvarez J., Mimura H., Ross F.P., et al. 1 Alpha,25-dihydroxyvitamin D3 up-regulates expression of the osteoclast integrin alpha v beta 3. J. Biol. Chem. 1993, 268:1456-1461.
141. Cao X., Ross F.P., Zhang L., MacDonald P.N., Chappel J., Teitelbaum S.L. Cloning of the promoter for the avian integrin beta 3 subunit gene and its regulation by 1,25-dihydroxyvitamin D3. J. Biol. Chem. 1993, 268:27371-27380.
142. Andersson G., Johansson E.K. Adhesion of human myelomonocytic (HL-60) cells induced by 1,25-dihydroxyvitamin D3 and phorbol myristate acetate is dependent on osteopontin synthesis and the alpha v beta 3 integrin. Connect. Tissue Res. 1996, 35:163-171.
143. Okada Y., Morimoto I., Ura K., Watanabe K., Eto S., Kumegawa M., et al. Cell-to-cell adhesion via intercellular adhesion molecule-1 and leukocyte function-associated antigen-1 pathway is involved in 1alpha,25(OH)2D3, PTH and IL-1alpha-induced osteoclast differentiation and bone resorption. Endocr. J. 2002, 49:483-495.
144. Kido S., Inoue D., Hiura K., Javier W., Ito Y., Matsumoto T. Expression of RANK is dependent upon differentiation into the macrophage/osteoclast lineage: induction by 1alpha,25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60. Bone 2003, 32:621-629.
145. Vincent C., Kogawa M., Findlay D.M., Atkins G.J. The generation of osteoclasts from RAW 264.7 precursors in defined, serum-free conditions. J. Bone Miner. Metab. 2009, 27:114-119.
146. Blair H.C., Zaidi M. Osteoclastic differentiation and function regulated by old and new pathways. Rev. Endocr. Metab. Disord. 2006, 7:23-32.
147. Lee B.S., Holliday L.S., Krits I., Gluck S.L. Vacuolar H+-ATPase activity and expression in mouse bone marrow cultures. J. Bone Miner. Res. 1999, 14:2127-2136.
148. Ke H.Z., Qi H., Crawford D.T., Simmons H.A., Xu G., Li M., et al. A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia. J. Bone Miner. Res. 2005, 20:1742-1755.
149. Bischoff-Ferrari H.A., Giovannucci E., Willett W.C., Dietrich T., Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 2006, 84:18-28.
150. Bischoff-Ferrari H.A., Willett W.C., Wong J.B., Giovannucci E., Dietrich T., Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005, 293:2257-2264.